Last reviewed · How we verify
SCB-2019 with Alum adjuvant
At a glance
| Generic name | SCB-2019 with Alum adjuvant |
|---|---|
| Sponsor | Clover Biopharmaceuticals AUS Pty |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (PHASE1)
- A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (PHASE2, PHASE3)
- Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (PHASE3)
- An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens (PHASE3)
- SCB-2019 as COVID-19 Vaccine (PHASE1)
- Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19. (PHASE1)
- Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19) (PHASE2)
- Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCB-2019 with Alum adjuvant CI brief — competitive landscape report
- SCB-2019 with Alum adjuvant updates RSS · CI watch RSS
- Clover Biopharmaceuticals AUS Pty portfolio CI